Why Apple Stock Is Rising Today And Could Be Headed To $200 Per Share
Apple Inc (NASDAQ: AAPL) shares are trading higher Monday following positive analyst coverage from Goldman Sachs.
Esperion Therapeutics Stock Is Diving: What’s Going On?
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are trading lower Monday after the company published new data on its treatment aimed at
Esperion Long Term Data On Cholesterol Medication’s Ability To Cut Cardiovascular Risk Fails To Impress Investors
Esperion Therapeutics Inc (NASDAQ:ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with…
Meme Token Rises 3% Amid Shiba Inu, Dogecoin Slide On Crypto.com Listing
Bone Shibaswap (CRYPTO: BONE) rose 3% in the last 24 hours, even as Shiba Inu (CRYPTO: SHIB), Dogecoin (CRYPTO:
Bitcoin, Ethereum, Dogecoin Slide As Silvergate Crumbles: Analyst Says Apex Crypto’s Streak ‘Has Been Broken’
Major coins traded in the red on Sunday evening as investors continued to digest crypto-friendly bank Silvergate Capital’s (NYSE: SI) failure.
12 Communication Services Stocks Moving In Friday’s After-Market Session
Gainers National CineMedia (NASDAQ:NCMI) shares moved upwards by 4.3% to $0.24 during Friday’s after-market session. The company’s market…
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 11.9% to $2.25 during Friday’s after-market session. The market value of their…
CareDx Earns Stock Downgrade Amid CMS Coverage Cuts Change Thesis
Raymond James downgraded CareDx Inc (NASDAQ:CDNA) to Market Perform from Strong Buy after MolDX issued a billing and coding article severely limiting coverage…
Analyst Upgrades This Radiology Stock, Expects Promising 2023 Ahead
Raymond James upgraded Radnet Inc (NASDAQ:RDNT) from Market Perform to Outperform and a price target of $30 following 4Q22 results that came in…
Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story
After the market close Thursday, Ardelyx Inc (NASDAQ:ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…